康莱特注射液联合FOLFIRI方案治疗晚期胃肠道肿瘤的临床观察

目的：探讨康莱特注射液联合FOLFIRI方案治疗晚期胃肠道肿瘤的疗效及毒副反应。方法：采用数字表法将94例晚期胃肠道肿瘤患者随机分成治疗组和对照组,治疗组采用康莱特注射液100ml,静滴,第1-7天,联合FOLFIRI方案治疗。对照组单用FOLFIRI方案化疗,2次为1个疗程,共6个疗程。观察临床有效率,毒副反应和生活质量。结果：治疗组和对照组化疗后临床有效率分别为34.1%和16.0%（P〈0.05）;治疗组和对照组生活质量提高分别为56.8%和12.0%（P〈0.05）;治疗组的骨髓抑制低于对照组（P〈0.05）,两组重度延迟性腹泻的发生率无显著差异（P〉0.05）。结论：康莱特注射液联合FOLFIRI方案治疗晚期胃肠道肿瘤能提高化疗疗效,改善患者的生活质量,降低骨髓抑制的发生率,起到减毒增效作用。

Clinical observation of compound Kanglaite injection combined with FOLFIRI regimen for patients with advanced gastrointestinal cancer

Objective：To investigate therapeutic effect of FOLFIRI regimen plus compound Kanglaite injection on advanced gastrointestinal cancer.Methods： Total of 94 patients with advanced gastrointestinal cancer were randomly divided into treatment group and control group by the digital table method.A combination of 100ml of the compound Kanglaite injection,7 days of intravenous drip and FOLFIRI was repeated every 2 weeks in the treatment group.The control group received only FOLFIRI chemotherapy at 2 times per cycle,6 cycles in all.RR,adverse reactions and quality of life were observed.Results： After chemotherapy RR,life quality and adverse reactions（bone marrow suppression） were improved significantly in the treatment group but not in the control group（P0.05）.Grade 3 or 4 diarrhea in 2 groups was similar（P0.05）.Conclusion： The compound Kanglaite injection plus FOLFIRI regimen could effectively improve RR and life quality and with light bone marrow suppression,and can decrease the toxity so as to enhance treatment effect.